(2) Derived from the audited financial statements included in the
Company's Annual Report on Form 10-K for the year-ended December 31,
2007.
ONYX PHARMACEUTICALS, INC.
RECONCILIATION OF GAAP TO NON-GAAP NET INCOME
(In thousands, except per share amounts)
(unaudited)
Three Months Ended Nine Months Ended
September 30, September 30,
--------------------------------------
2008 2007 2008 2007
---------- -------- -------- ---------
GAAP net income (loss) $12,243 $555 $32,135 $(22,465)
Non-GAAP adjustments:
Employee stock-based compensation
under FAS 123R 4,340 3,641 13,809 10,266
---------- -------- -------- ---------
Non-GAAP net income (loss) (3) $16,583 $4,196 $45,944 $(12,199)
========== ======== ======== =========
GAAP diluted net income (loss) per
share $0.21 $0.01 $0.57 $(0.45)
Non-GAAP adjustments:
Employee stock-based compensation
under FAS 123R 0.08 0.07 0.24 0.21
Non-GAAP diluted net income (loss) ---------- -------- -------- ---------
per share (3) $0.29 $0.08 $0.81 $(0.24)
=========== ======== ======== =========
Diluted shares 57,194 55,785 56,773 49,817
(3) This press release includes the following non-GAAP financial measures:
non-GAAP net income (loss
'/>"/>
| SOURCE Onyx Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |